References in periodicals archive ?
* A review of the Oropharyngeal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients.
Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV infected children multicenter study group.
Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS.
Several authors have reported that apart from prolonged exposure, advanced immunosuppression is a major risk factor for azole resistance [16].In the present study, among the 150 HIV patients with oropharyngeal candidiasis, 70.7% had CD4 count <200 cells/[mm.sup.3] which was statistically significant by proportional test (p = <0.001) This correlated well with the study conducted by Usha et al [17] where 76.66% patients with oropharyngeal candidiasis had CD4 count <200 cells/[micro]l.
emphasizes the need for speciation and determination of antifungal susceptibility pattern of the oral candida isolates from HIV patients with oropharyngeal candidiasis.
Loramyc is an antifungal drug indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients.
(Woodcliff Lake, NJ) entered into an exclusive licensing agreement under which Par will receive commercialization rights in the United States to BioAlliance Pharma's Loramyc (miconazole Lauriad), an innovative antifungal therapy currently in Phase III development for the treatment of oropharyngeal candidiasis, an opportunistic infection commonly found in immunocompromised patients, including those with HIV and cancer.
Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients.
Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 2006; 19:80-4.